Through the partnership, Liaison’s clients and their partners can leverage the validation and security of the SAFE-BioPharma standard, which verifies and manages digital identities and signatures involved in electronic transactions.
“Liaison’s enablement of the SAFE-BioPharma standard in a cloud-based platform is important to life sciences organizations as they utilize this important technology,” said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association.
The standard was designed to speed transformation of the biopharmaceutical and healthcare communities to a fully digital environment, while mitigating legal, regulatory and other business risks associated with electronic transactions. Recognized by the DEA and in line with HIPAA regulations, the standard provides a way to verify the identities of parties involved in business-to-business and business-to-regulator electronic transactions.
“Collaborating with SAFE-BioPharma shows an ongoing commitment to ensuring our cloud-based services are supported by industry standards that enhance the quality and security of patient and other sensitive data,” said Gary Palgon, Liaison’s vice president of healthcare solutions.
Earlier this year, Liaison announced a healthcare partner program in an effort to expand services available to clients so they can more easily exchange information in light of the HITECH Act and new models of care.